November 13, 2017
1 min read

Hydrus canal stent meets study endpoint

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Paul J. Harasymowycz

NEW ORLEANS — Two-year results of the HORIZON study show that 77.2% of patients implanted with a Hydrus microstent achieved the primary endpoint of a 20% reduction in washed-out IOP compared with 57.8% of patients who underwent cataract surgery only.

In the HORIZON study, 556 patients with cataract and mild to moderate glaucoma were randomly assigned to cataract surgery with the Hydrus (Ivantis) or to cataract surgery alone.

“Whenever we do combined surgery, the cataract effect weans off over time and perhaps that’s why these stents are working,” Paul J. Harasymowycz, MD, said at Glaucoma Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Canal stenting lowers IOP by increasing outflow through the eyes’ natural pathway, although proper device placement and patient selection are crucial for success, he said.

“It is microinvasive [surgery], but major complications can occur. [However], it is important to offer patients a chance to decrease the medical burden of the disease,” Harasymowycz said. “We’re very fortunate that new canal stent options will be available very soon.” – by Patricia Nale, ELS



Harasymowycz PJ. Canal stenting: Into Schlemm’s and beyond. Presented at AAO Subspecialty Days; Nov. 10-11, 2017; New Orleans.


Disclosure: Harasymowycz reports consulting relationships with Glaukos, Ivantis and Alcon/Novartis.